Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients.

Safroneeva, Ekaterina; Vavricka, S; Fournier, N; Seibold, Frank Werner; Mottet, C; Nydegger, A; Ezri, J; Straumann, A; Rogler, G; Schoepfer, A M; Juillerat, Pascal; Swiss IBD Cohort, Study Group (2015). Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. Alimentary pharmacology & therapeutics, 42(5), pp. 540-548. Wiley-Blackwell 10.1111/apt.13307

	Text Safroneeva AlimentPharmacolTher 2015_p540.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (484kB)
	Text Safroneeva AlimentPharmacolTher 2015_p540_corrigendum.pdf - Other Restricted to registered users only Available under License Publisher holds Copyright. Download (135kB)

BACKGROUND

Studies that systematically assess change in ulcerative colitis (UC) extent over time in adult patients are scarce.

AIM

To assess changes in disease extent over time and to evaluate clinical parameters associated with this change.

METHODS

Data from the Swiss IBD cohort study were analysed. We used logistic regression modelling to identify factors associated with a change in disease extent.

RESULTS

A total of 918 UC patients (45.3% females) were included. At diagnosis, UC patients presented with the following disease extent: proctitis [199 patients (21.7%)], left-sided colitis [338 patients (36.8%)] and extensive colitis/pancolitis [381 (41.5%)]. During a median disease duration of 9 [4-16] years, progression and regression was documented in 145 patients (15.8%) and 149 patients (16.2%) respectively. In addition, 624 patients (68.0%) had a stable disease extent. The following factors were identified to be associated with disease progression: treatment with systemic glucocorticoids [odds ratio (OR) 1.704, P = 0.025] and calcineurin inhibitors (OR: 2.716, P = 0.005). No specific factors were found to be associated with disease regression.

CONCLUSIONS

Over a median disease duration of 9 [4-16] years, about two-thirds of UC patients maintained the initial disease extent; the remaining one-third had experienced either progression or regression of the disease extent.

Interest & Impact

Downloads

2 since deposited on 09 Feb 2016
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item